share_log

藥明康德:2024年第一季度報告

WUXI APPTEC: 2024 FIRST QUARTERLY REPORT

Hong Kong Stock Exchange ·  Apr 29 09:03
Summary by Moomoo AI
药明康德於2024年4月29日發布2024年第一季度報告,顯示營業收入及淨利潤分別下降10.95%及10.42%。未經審計的報告顯示,公司營業收入為約798億元人民幣,歸屬於上市公司股東的淨利潤約為19.4億元人民幣。經營活動產生的現金流量淨額下降25.44%,基本每股收益為0.67元。公司總資產輕微增長至約749億元人民幣,歸屬於上市公司股東的所有者權益也小幅增加至約556億元人民幣。報告期內,药明康德新增客戶超過300家,服務的活躍客戶超過6,000家,並成功合成並交付超過43萬個新化合物。公司持續強化其CRDMO和CTDMO業務模式,並在全球範圍內提供一體化的新藥研發和生產服務。
药明康德於2024年4月29日發布2024年第一季度報告,顯示營業收入及淨利潤分別下降10.95%及10.42%。未經審計的報告顯示,公司營業收入為約798億元人民幣,歸屬於上市公司股東的淨利潤約為19.4億元人民幣。經營活動產生的現金流量淨額下降25.44%,基本每股收益為0.67元。公司總資產輕微增長至約749億元人民幣,歸屬於上市公司股東的所有者權益也小幅增加至約556億元人民幣。報告期內,药明康德新增客戶超過300家,服務的活躍客戶超過6,000家,並成功合成並交付超過43萬個新化合物。公司持續強化其CRDMO和CTDMO業務模式,並在全球範圍內提供一體化的新藥研發和生產服務。
MINGKAND PHARMACEUTICALS RELEASED ITS FIRST QUARTER REPORT FOR 2024 ON 29 APRIL 2024, SHOWING A DECREASE IN REVENUE AND NET PROFIT OF 10.95% AND 10.42%, RESPECTIVELY. The unaudited report showed that the company had an operating income of about RMB 798 billion and a net profit attributable to shareholders of listed companies of about RMB 19.4 billion. Net cash flow generated by operating activities decreased 25.44% with basic earnings per share of $0.67. The company's total assets increased slightly to about RMB 749 billion, while the shareholders' equity belonging to the listed company's shareholders also increased slightly to about RMB 556 billion. During the reporting period, Mincond Pharmaceuticals added more than 300 customers, served more than 6,000 active customers, and successfully synthesized and delivered more than 43 million new compounds. The company continues to strengthen its CRDMO and CTDMO business models and provides integrated new drug R&D and production services globally.
MINGKAND PHARMACEUTICALS RELEASED ITS FIRST QUARTER REPORT FOR 2024 ON 29 APRIL 2024, SHOWING A DECREASE IN REVENUE AND NET PROFIT OF 10.95% AND 10.42%, RESPECTIVELY. The unaudited report showed that the company had an operating income of about RMB 798 billion and a net profit attributable to shareholders of listed companies of about RMB 19.4 billion. Net cash flow generated by operating activities decreased 25.44% with basic earnings per share of $0.67. The company's total assets increased slightly to about RMB 749 billion, while the shareholders' equity belonging to the listed company's shareholders also increased slightly to about RMB 556 billion. During the reporting period, Mincond Pharmaceuticals added more than 300 customers, served more than 6,000 active customers, and successfully synthesized and delivered more than 43 million new compounds. The company continues to strengthen its CRDMO and CTDMO business models and provides integrated new drug R&D and production services globally.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more